Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
ActiTrexx GmbH logo — ATreg - For a life without Transplant Rejection

ActiTrexx GmbH

ATreg - For a life without Transplant Rejection

Founded 2020 Germany Mainz, Germany 7 employees Series A Total: $3.50M Biotechnology

General Information

Company Name ActiTrexx GmbH
Founded Year 2020
Location Germany Mainz, Germany +1
Employees 7
Industries Biotechnology
Funding Stage Series A
Social

Get notified when ActiTrexx GmbH moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About ActiTrexx GmbH

ActiTrexx GmbH is a biotech startup founded in 2020, with a vision to provide a curative cellular therapy to prevent inflammatory reactions in conditions such as GvHD, solid organ transplantation, and autoimmune diseases. The company's flagship product, ATreg, leverages regulatory T cells (Treg) to offer a safe and efficient treatment option for transplanted patients, with the potential to substantially decrease GvHD severity and related mortality. The management team of ActiTrexx GmbH brings together extensive experience in basic research, biotechnology, clinical application, and pharmaceutical development. Supported by a strong network of collaborators, advisors, key opinion leaders, and experienced managers, the company is well-positioned to advance its innovative cellular therapy. In March 2021, the company secured a significant €3.50M Series A investment from a group of notable investors, including HTGF | High-Tech Gruenderfonds, MediVentures, LBBW VC, Investitions- und Strukturbank Rheinland-Pfalz, underscoring the confidence in the potential of ActiTrexx's approach. With its headquarters in Mainz, Germany, ActiTrexx GmbH is poised to make impactful strides in the biotechnology industry.

Taxonomy: biotech startup, cellular therapy, regulatory T cells, immune system, inflammatory reactions, GVHD, solid organ transplantation, autoimmune diseases, cell-based drug product, ATreg, clinical application, pharmaceutical development, Mainz, Germany, regenerative medicine, immunotherapy

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 4 •••• •••• 02 Mar 2021

ActiTrexx GmbH Alternatives & Competitors

ActiTrexx GmbH vs
Coya Therapeutics, Inc.
Coya Therapeutics, Inc. United States

Unleashing the power of Tregs to tackle neurodegenerative and autoimmune diseases.

Unknown
17 employees
Biopharma, Biotechnology
ActiTrexx GmbH vs
Abintus Bio, Inc.
Abintus Bio, Inc. United States

Empowering patients from within

Series Unknown
11 employees
Biotechnology, Health Care
ActiTrexx GmbH vs
CytoVac AB
CytoVac AB

Biotech company with Phase II Clinical Trials - ALECSAT - CAR-T cell therapy - Orphan Drug

Series Unknown
10 employees
Biotechnology, Health Care

FAQ About ActiTrexx GmbH

ATreg - For a life without Transplant Rejection
ActiTrexx GmbH was founded in 2020.
ActiTrexx GmbH is headquartered in Mainz, Germany.
ActiTrexx GmbH operates in the following industries: Biotechnology.
ActiTrexx GmbH has approximately 7 employees.
ActiTrexx GmbH has completed 1 funding round, raising a total of $3.50M. The latest funding stage is Series A.
Top alternatives and competitors to ActiTrexx GmbH include Coya Therapeutics, Inc., Abintus Bio, Inc., CytoVac AB, CellSight Technologies Inc., MiNK Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ActiTrexx GmbH and Coya Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors ActiTrexx GmbH and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy